Andere talen Black Diamond Therapeutics, Inc. OTC Markets

Aandelen

BDTX

US09203E1055

Geschatte realtime Cboe BZX Andere beurzen 16:16:13 06-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,59 ^USD	0,00%		0,00%	0,00%

01/06	Black Diamond Therapeutics, Inc. Presenteert veelbelovende klinische gegevens van Bdtx-1535 bij patiënten met terugkerend glioblastoom op de jaarlijkse bijeenkomst van de American Society of Clinical Oncology (Asco) in 2024	CI
16/05	BLACK DIAMOND THERAPEUTICS, INC. : HC Wainwright handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01/06
Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	01/06
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	01/06
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	29/05
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	29/05
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Black Diamond: Q1 Earnings Snapshot	09/05
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K	09/05
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	11/04
Black Diamond Therapeutics Announces Changes to Board of Directors	11/04
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	08/04
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08/04
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08/04
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	03/04
Black Diamond: Q4 Earnings Snapshot	12/03
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Black Diamond Therapeutics, Inc. OTC Markets

Aandelen

BDTX

US09203E1055

Andere talen

Filters